Photo from wikipedia
Pembrolizumab is an immune checkpoint inhibitor designed to block the interaction between programmed cell death‐1 and programmed cell death‐ligands 1 and 2. It shows efficacy in the treatment of patients… Click to show full abstract
Pembrolizumab is an immune checkpoint inhibitor designed to block the interaction between programmed cell death‐1 and programmed cell death‐ligands 1 and 2. It shows efficacy in the treatment of patients with advanced nonsmall‐cell lung cancer, among others. Side effects may involve immune‐related adverse events, including vitiligo.
Keywords:
vitiligo patient;
induced vitiligo;
pembrolizumab induced;
pembrolizumab;
patient lung;
lung
Journal Title: British Journal of Clinical Pharmacology
Year Published: 2020
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!
Journal Title: British Journal of Clinical Pharmacology
Year Published: 2020
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!